Source - LSE Regulatory
RNS Number : 2455D
OptiBiotix Health PLC
25 June 2019
 

OptiBiotix Health plc

("OptiBiotix")

 

Appointment of goetzpartners securities Limited

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high

cholesterol, diabetes and skin care, announces the appointment of goetzpartners securities Limited ("GPSL").  GPSL  will provide financial advisory services to OptiBiotix Health Plc including sector specific equity research and investor support services. These services will be provided in addition to the services provided by OptiBiotix's current broker, finnCap, extending the companies reach into European investment markets.

 

GPSL is a member of the goetzpartners group and a leading pan-European investment banking and corporate broking firm dedicated to the healthcare sector. GPSL bring together a wide range of investment, research, and sector expertise, with the group's global footprint, to advance the interests of clients in the healthcare sector.

 

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the appointment of goetzpartners securities Limited. The appointment is intended to improve international institutional and family funds buy side access, particularly from within Europe, and to provide expert research analysis which can be distributed to specialist institutional investors around the world. With OptiBiotix's products now being commercialised in over 30 countries around the world this is a strategic step to broaden the Company's investors base with the support of a leading pan-European investment bank and research company specialising in heathcare and technology."

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

For further information, please contact:

 

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below



Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0880

Liam Murray / Jo Turner / Ludovico Lazzaretti


 

finnCap (Broker)

 

Tel: 020 7220 0500

Geoff Nash / Kate Bannatyne (Corporate Finance)


Camille Gochez (Corporate Broking)



 

goetzpartners securities Limited

 Tel: 020 3897 6663

Brigitte de Lima




Walbrook PR Ltd

Tel: 020 7933 8780 or optibiotix@walbrookpr.com

Anna Dunphy

Mob: 07876 741 001

 

 

 

 

 

 

 

 

 

About OptiBiotix - www.optibiotix.com 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. 

 

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

 

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
APPLLFFERTISFIA
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.